High-Grade B-Cell Lymphomas, Not Otherwise Specified: A Study of 41 Cases
Authors Li J, Liu X, Yao Z, Zhang M
Received 26 December 2019
Accepted for publication 3 March 2020
Published 13 March 2020 Volume 2020:12 Pages 1903—1912
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 2
Editor who approved publication: Dr Yong Teng
Jiayin Li, 1, 2 Xiaoyin Liu, 3 Zhihua Yao, 4 Mingzhi Zhang 1, 2
1Department of Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan 450000, People’s Republic of China; 2Lymphoma Diagnosis and Treatment Center of Henan Province, Zhengzhou, Henan 450000, Republic of China; 3Department of Hematology, People’s Hospital of Zhengzhou University, Zhengzhou, Henan 450003, People’s Republic of China; 4Department of Internal Medicine, The Affiliated Cancer Hospital of Zhengzhou University (Henan Cancer Hospital), Zhengzhou, Henan 450008, People’s Republic of China
Correspondence: Mingzhi Zhang
Department of Oncology, The First Affiliated Hospital of Zhengzhou University, No. 1 Jianshe East Road, Zhengzhou, Henan 450052, People’s Republic of China
Tel +86 371 6629 5562
Fax +86 371 6629 5563
Purpose: To analyze the clinical and pathological characteristics, treatment, and prognosis of high-grade B-cell lymphomas, not otherwise specified (HGBL, NOS), and to increase awareness of this type of lymphoma.
Patients and Methods: We collected clinical and pathological data of 41 cases of newly diagnosed HGBL, NOS, and analyzed diagnosis, prognosis and treatment to examine progression-free survival (PFS) and overall survival (OS).
Results: Among the 41 cases studied, the median PFS was 6.0 months and the median OS was 18.0 months. Compared with patients treated with the R-CHOP regimen, patients treated with a high-intensity chemotherapy (DA-EPOCH-R, R-CODOX-M/IVAC, or R-Hyper-CVAD) had superior PFS and OS (PFS: χ 2=4.173, P=0.041; OS: χ 2=5.200, P=0.023). A subgroup analysis showed that the OS for the double-expressor lymphoma (DEL) was inferior to that for the non-DEL (χ 2=4.563, P=0.033), and this trend was also seen for the single-hit lymphoma with MYC rearrangement (SHL) and the non-SHL (χ 2=4.955, P=0.026). Patients with low International Prognostic Index (IPI) scores (≤ 2) had better survival rates than those with high scores (> 2) (PFS: χ 2=6.482, P=0.011; OS: χ 2=10.156, P=0.001).
Conclusion: HGBL, NOS is associated with a high degree of malignancy, short survival period, and substantial extranodal involvement. High-intensity chemotherapy may improve patient prognosis. While IPI scores statistically correlated with the prognosis, SHL and DEL correlated with an inferior survival rate. New and improved treatments will be needed for HGBL, NOS.
Keywords: HGBL, NOS, clinical and pathological, treatment, prognosis
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.Download Article [PDF] View Full Text [HTML][Machine readable]